Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 20Breast Neoplasms 11Prostatic Neoplasms 10Neoplasms 7Neoplasm Metastasis 7Fallopian Tube Neoplasms 7Pancreatic Neoplasms 6Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Lung Neoplasms 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1SCLC,Extensive Stage 1Recurrence 1Rectal Neoplasms 1Prostate Adenocarcinoma 1

Interventions

niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-sensitive Prostate Cancer × niraparib × 1 year × Clear all
NCT04497844 2026-06-05

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡